Tectonic Therapeutic, Inc. (NASDAQ:TECX – Get Free Report) insider Marcella Ruddy sold 1,000 shares of Tectonic Therapeutic stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $31.05, for a total transaction of $31,050.00. Following the sale, the insider directly owned 68,747 shares of the company’s stock, valued at $2,134,594.35. This represents a 1.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Tectonic Therapeutic Price Performance
TECX stock opened at $30.52 on Monday. Tectonic Therapeutic, Inc. has a twelve month low of $13.70 and a twelve month high of $36.03. The company has a market cap of $573.17 million, a P/E ratio of -7.54 and a beta of 3.59. The business’s fifty day moving average is $26.32 and its 200-day moving average is $21.31.
Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.03) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.08. Research analysts anticipate that Tectonic Therapeutic, Inc. will post -8.31 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Tectonic Therapeutic
Analyst Upgrades and Downgrades
TECX has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tectonic Therapeutic in a research note on Thursday, January 22nd. Truist Financial decreased their price objective on shares of Tectonic Therapeutic from $64.00 to $60.00 and set a “buy” rating for the company in a report on Thursday, January 8th. Finally, Lifesci Capital raised shares of Tectonic Therapeutic to a “strong-buy” rating in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $81.50.
Check Out Our Latest Report on Tectonic Therapeutic
About Tectonic Therapeutic
Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
See Also
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
